ImmunityBio Shares 11% Higher on License Application Resubmission for N-803
23 Outubro 2023 - 12:00PM
Dow Jones News
By Dean Seal
Shares of ImmunityBio rose after the company resubmitted a
biological license application for its investigational bladder
cancer treatment N-803.
The stock was up 11% at $1.44 in early trading. Shares have
fallen 71% year-to-date.
The clinical-stage immunotherapy company said Monday that it
resubmitted the application to the U.S. Food and Drug
Administration.
The application is supported by the results of ImmunityBio's
studies in bladder cancer, including a study published last
November.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
October 23, 2023 10:45 ET (14:45 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
ImmunityBio (NASDAQ:IBRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
ImmunityBio (NASDAQ:IBRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
